This jointly organised meeting of the RSC BMCS, DMDG and Drug Metabolism Group, was held at Royal Society of Chemistry in Burlington House on 21-22 May 2018.
Over the two-day event, participants heard about recent research in drug discovery and development, spanning a wide range of topics; main sessions covered the broad areas of reactive metabolites and adverse reactions, chemical aspects of large molecules development, and medicinal chemistry approaches to improved metabolism, as well as a ‘hot topics’ session.
A keynote address by Douglas Spracklin (Pfizer, USA) set the scene for the meeting, providing an overview of the strategies and methods that have been developed for efficient, biocatalytic lead diversification.
Given the location of the meeting, a fitting central theme of the meeting was the need to understand the fundamental chemical principles underlying the observed biology, whether that be related to compound properties, kinetics, quantitation, or identification.
In addition to the platform presentations, participants had meeting-long access to the scientific posters and exhibitor stands, which continued this narrative and demonstrated the diversity and high level of activity in the DMPK arena.
Toby Athersuch
Drug Metabolism Group (DMG) Chairman
The 5th New Perspectives in DMPK conference will take place in early 2020. Details will be made available via the RSC BMCS, DMDG and DMG websites in mid 2019.
www.rsc.org/Membership/Networking/InterestGroups/BMCS
www.thedrugmetabolismgroup.com
www.dmdg.org